Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?

Molecular Diagnosis & Therapy(2021)10.1007/s40291-021-00534-6Source: DataRank Database

Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology? is a research paper published in Molecular Diagnosis & Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 49 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access49 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.68)OA: hybridTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Hunter R. Underhill ORCID

Live enrichment

PubMed:34018157 PMC:PMC8249304 OpenAlex:https://openalex.org/W3160863178

National Cancer Institute

Grant: R37CA246183

National Institutes of Health

Grant: 5R37CA246183-03

Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma

FWCI

2.68

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://link.springer.com/content/pdf/10.1007/s40291-021-00534-6.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40291-021-00534-6.pdf

publisherhttps://link.springer.com/article/10.1007/s40291-021-00534-6/fulltext.html

journalhttps://doi.org/10.1007/s40291-021-00534-6

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34018157

Fields of Study

Cancer Genomics and DiagnosticsSingle-cell and spatial transcriptomicsCancer Cells and Metastasis0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Circulating Tumor DNAGene FrequencyHumansMutationNeoplasmsSensitivity and SpecificitySequence Analysis, DNAEarly Detection of CancerPrecision MedicineHigh-Throughput Nucleotide Sequencing

Keywords

Molecular diagnosticsBiologySomatic cellComputational biologyPrecision medicineDNA sequencingMalignancyDNABioinformaticsGeneticsGeneHigh-Throughput Nucleotide SequencingSequence Analysis, DNASensitivity and SpecificityCirculating Tumor DNAGene FrequencyCurrent OpinionNeoplasmsMutationHumansEarly Detection of Cancer

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?

FAIR Checklist

Authors (1)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)